v3.24.1.1.u2
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
CASH FLOWS FROM OPERATING ACTIVITIES    
Net loss $ (4,612) $ (2,300)
Adjustments to reconcile net loss to net cash used in operating activities:    
Stock-based compensation 274 181
Depreciation and amortization 212 182
Loss on extinguishment of warrant liability 0 504
Change in fair value of warrant liability 23 (5,606)
Gain on issuance of convertible note 0 (64)
Amortization of debt discount 0 374
Change in fair value of notes 0 117
Amortization of deferred debt issuance costs 944 1,635
Amortization of right-of-use assets 168 133
Other expenses 0 1,206
Changes in operating assets and liabilities:    
Prepaid and other assets (111) (161)
Accounts receivable (693) 0
Note receivables (576) 0
Deferred revenue 1,260 0
Accounts payable 797 125
Accrued expenses (228) (920)
Lease liabilities (171) (134)
Warranty customer liability 36 0
Net cash used in operating activities (2,677) (4,728)
CASH FLOWS FROM INVESTING ACTIVITIES    
Cash paid for acquisition of Amerigen 7 0 (645)
Purchase of equipment (63) (435)
Net cash used in investing activities (63) (1,080)
CASH FLOWS FROM FINANCING ACTIVITIES    
Proceeds from the exercise of warrants 0 2,062
Proceeds from the issuance of common stock and warrants, net of fees 0 0
Proceeds from the issuance of common stock / at-the-market offering, net of offering costs 588 2,107
Proceeds from issuance of notes in connection with Line of Credit 0 2,000
Proceeds from issuance of January promissory notes, net of fees paid 0 970
Repayment of notes payable (8) (14)
Proceeds from the issuance of common stock in connection with equity line of credit, net of offering costs 1,391 0
Net cash provided by financing activities 1,971 7,125
Net increase / decrease in cash (769) 1,317
Cash — beginning of period 1,059 821
Cash — end of period 290 2,138
SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:    
Issuance of Series E preferred stock in connection with line of credit 0 4,350
Issuance of common stock in connection with conversion of notes 0 516
Commitment to issue shares of common stock in connection with March Waiver agreement 0 298
Deemed dividend for repricing of series D preferred stock 0 6
Unpaid equipment included in accounts payable 0 156
SUPPLEMENTAL CASH FLOW INFORMATION    
Cash paid for interest $ 0 $ 8

Source

PDF HTML
10-Q Filing
ZIP XLS HTML
XBRL